公开(公告)号：US20170242020A1

公开(公告)日：2017-08-24

申请号：US15310065

申请日：2015-05-29

Applicant: The Regents of the University of California

Inventor： Kevin A. Yamauchi ,  Amy E. Herr

IPC: G01N33/68 ,  G01N27/447 ,  G01N33/543 ,  G01N33/545 ,  G01N33/561

CPC classification number: G01N33/6803 ,  C07K1/26 ,  C12N15/101 ,  C12Q2565/125 ,  G01N27/44747 ,  G01N27/44756 ,  G01N27/44791 ,  G01N33/54306 ,  G01N33/545 ,  G01N33/561 ,  G01N2550/00 ,  G01N2570/00

Abstract: Electrophoretic separation methods and systems for performing the same are provided. The methods and systems find use in a variety of different electrophoretic separation applications, such as sub-cellular Western blotting of single cells.

公开(公告)号：US20170204145A1

公开(公告)日：2017-07-20

申请号：US15326759

申请日：2015-07-07

Applicant: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA) ,  INSTITUT PASTEUR DE LILLE (IPL)

Inventor： Gwenael JAN ,  Benoit FOLIGNE ,  Helene FALENTIN ,  Stephanie-Marie DEUTSCH

IPC: C07K14/195 ,  C12Q1/04

CPC classification number: C07K14/195 ,  A61K38/00 ,  A61K38/164 ,  C12Q1/04 ,  G01N2333/195 ,  G01N2550/00

Abstract: Disclosed is a polypeptide including or consisting of the amino acid sequence SEQ id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid sequence and/or a vector, for use in the treatment or prevention of an inflammatory disease. Also disclosed is a pharmaceutical composition or a food composition including a polypeptide, a nucleic acid sequence, a vector or a host cell and a pharmaceutically acceptable carrier or a dairy product, for the treatment of inflammatory disease. Additionally, a method for the screening of bacteria having immunomodulatory properties is disclosed.

公开(公告)号：US20160341735A1

公开(公告)日：2016-11-24

申请号：US15138177

申请日：2016-04-25

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Thomas DILLER ,  Bethany Sutton ,  George Hanson ,  Timothy Updyke

IPC: G01N33/58

CPC classification number: G01N33/582 ,  B33Y80/00 ,  G01N33/6803 ,  G01N2550/00

Abstract: The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest.

公开(公告)号：US20160252536A1

公开(公告)日：2016-09-01

申请号：US15152022

申请日：2016-05-11

Applicant: True Health Diagnostics LLC

Inventor： Philip Guadagno ,  Erin Bellin

IPC: G01N33/92 ,  G01N27/447 ,  G01N21/64

CPC classification number: G01N33/92 ,  G01N21/6428 ,  G01N21/6456 ,  G01N27/44726 ,  G01N27/44747 ,  G01N27/44756 ,  G01N33/561 ,  G01N2021/6441 ,  G01N2021/7786 ,  G01N2333/775 ,  G01N2550/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present invention relates to, among other things, a gel electrophoresis system for detecting the level of specific Apolipoproteins and/or lipoprotein particles present in intact lipid particles in a biological sample. The system includes a gel substrate to receive a biological sample, at least two lipoprotein-binding complexes. Each complex includes an antibody that binds a lipoprotein particle or a portion thereof, which is bound to a signal producing molecule capable of producing or causing production of a detectable signal. The system also includes a device for detecting the detectable signal. The present invention also relates to methods of assessing the level of specific Apolipoproteins and/or lipoprotein particles present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease, and monitoring the risk for developing cardiovascular disease.

Abstract translation: 本发明尤其涉及用于检测存在于生物样品中完整脂质颗粒中的特定载脂蛋白和/或脂蛋白颗粒的水平的凝胶电泳系统。 该系统包括用于接收生物样品的凝胶底物，至少两种脂蛋白结合复合物。 每个复合物包括结合脂蛋白颗粒或其部分的抗体，其结合于能够产生或引起产生可检测信号的信号产生分子。 该系统还包括用于检测可检测信号的装置。 本发明还涉及评估生物样品中存在的特定载脂蛋白和/或脂蛋白颗粒的水平的方法，确定受试者是否处于心血管疾病风险增加以及监测发展心血管疾病的风险。

公开(公告)号：US20150276733A1

公开(公告)日：2015-10-01

申请号：US14576470

申请日：2014-12-19

Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE ,  CHANG GUNG MEMORIAL HOSPITAL, LINKOU

Inventor： Pai-chien CHOU ,  Bo-Wen XIAO ,  Ming-Hua YEH ,  Sin-Huei WU

IPC: G01N33/561

CPC classification number: G01N33/561 ,  G01N2550/00

Abstract: The present disclosure provides an optical readout imaging system may include first electrode, a thin film disposed on the first electrode, a biomolecule transfer layer disposed on the thin film, and a second electrode disposed on the biomolecule transfer layer. The present disclosure also provides a biochemical detection method using the optical readout imaging system.

Abstract translation: 本公开提供了一种光学读出成像系统可以包括第一电极，设置在第一电极上的薄膜，设置在薄膜上的生物分子转移层和设置在生物分子转移层上的第二电极。 本公开还提供了使用光学读出成像系统的生物化学检测方法。

公开(公告)号：US20140234979A1

公开(公告)日：2014-08-21

申请号：US14079330

申请日：2013-11-13

Applicant: LIFE TECHNOLOGIES CORPORATION

Inventor： Thomas DILLER ,  Bethany Sutton ,  George Hanson ,  Timothy Updyke

IPC: G01N33/58

CPC classification number: G01N33/582 ,  B33Y80/00 ,  G01N33/6803 ,  G01N2550/00

Abstract: The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein. Following the labeling step, the proteins within the mixture can be separated and analyzed. In a further embodiment, a tag binding fluorogenic reagent that can bind to a tag on a tagged protein is added to specifically label the protein of interest.

Abstract translation: 本发明提供用于在细胞裂解物或蛋白质混合物中标记，分离和分析蛋白质，特别是感兴趣的特定蛋白质的方法和组合物。 蛋白质用胺反应性或硫醇反应性荧光染料或胺反应性荧光试剂标记，其与位于蛋白质上的胺基团反应变为荧光。 在标记步骤之后，可以分离和分析混合物内的蛋白质。 在另一个实施方案中，加入可结合标记蛋白上的标签的标签结合荧光试剂以特异性标记所关注的蛋白质。

公开(公告)号：US20130248370A1

公开(公告)日：2013-09-26

申请号：US13896765

申请日：2013-05-17

Applicant: BOSTON HEART DIAGNOSTICS CORPORATION

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N27/447

CPC classification number: G01N33/561 ,  C12M33/00 ,  G01N27/44739 ,  G01N27/44747 ,  G01N27/44778 ,  G01N33/54386 ,  G01N33/6842 ,  G01N33/92 ,  G01N2333/775 ,  G01N2550/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are methods and apparatus for separation of biomolecules via two-dimensional gel electrophoresis, methods and apparatus for immunoblotting separated biomolecules, and methods for the use of biomolecules processed via the methods and apparatus of the present invention, including use in a clinical setting. The methods and apparatus for separation of biomolecules via two-dimensional gel comprises vertical agarose gel electrophoresis in the first dimension, and the electrophoresis of a novel non-denaturing 3-35% concave gradient polyacrylamide gel in the second dimension. This novel gel can be cast in a modified gel caster that can facilitate the pouring of multiple gels simultaneously. The methods and apparatus for immunblotting are useful with any type of immunoblotting, including Western blot, Northern blot, and Southern blot analyses. These methods and apparatus provide safe, efficient and cost-effective immunoblots, while facilitating the reduction of exposure to toxic or radioactive materials, as well as the disposal of those materials.

Abstract translation: 公开了通过二维凝胶电泳分离生物分子的方法和装置，用于免疫印迹分离的生物分子的方法和装置，以及使用通过本发明的方法和装置处理的生物分子的方法，包括在临床环境中的用途。 通过二维凝胶分离生物分子的方法和装置包括第一维中的垂直琼脂糖凝胶电泳和第二维中新型非变性3-35％凹梯度聚丙烯酰胺凝胶的电泳。 这种新型凝胶可以浇铸在改良的凝胶浇铸机中，可以同时使多个凝胶倾倒。 用于免疫印迹的方法和装置可用于任何类型的免疫印迹，包括Western印迹，Northern印迹和Southern印迹分析。 这些方法和设备提供安全，有效和经济有效的免疫印迹，同时有助于减少暴露于有毒或放射性物质以及处理这些材料。

公开(公告)号：US08541184B2

公开(公告)日：2013-09-24

申请号：US13015288

申请日：2011-01-27

Applicant: Paul Alan Cox ,  Sandra Banack ,  Susan Murch

Inventor： Paul Alan Cox ,  Sandra Banack ,  Susan Murch

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N33/6812 ,  G01N33/94 ,  G01N2410/00 ,  G01N2550/00 ,  G01N2800/28 ,  Y02A50/57

Abstract: Methods for screening for neurological disorders are disclosed. Specifically, methods are disclosed for screening for neurological disorders in a subject by analyzing a tissue sample obtained from the subject for the presence of elevated levels of neurotoxic amino acids or neurotoxic derivatives thereof associated with neurological disorders. In particular, methods are disclosed for diagnosing a neurological disorder in a subject, or predicting the likelihood of developing a neurological disorder in a subject, by determining the levels of β-N-methylamino-L-alanine (BMAA) in a tissue sample obtained from the subject. Methods for screening for environmental factors associated with neurological disorders are disclosed. Methods for inhibiting, treating or preventing neurological disorders are disclosed.

Abstract translation: 公开了筛选神经障碍的方法。 具体地，公开了通过分析从受试者获得的组织样品中存在与神经系统疾病相关的神经毒性氨基酸或神经毒性衍生物的升高水平来筛选受试者神经障碍的方法。 具体地，通过确定获得的组织样品中的β-N-甲基氨基-L-丙氨酸（BMAA）的水平，公开了用于诊断受试者的神经障碍或预测受试者发展神经障碍的可能性的方法 从主题。 公开了与神经障碍相关的环境因素的筛选方法。 公开了抑制，治疗或预防神经障碍的方法。

公开(公告)号：US08470541B1

公开(公告)日：2013-06-25

申请号：US12567737

申请日：2009-09-26

Applicant: Bela F. Asztalos ,  Ernst J. Schaefer

Inventor： Bela F. Asztalos ,  Ernst J. Schaefer

IPC: G01N33/53

CPC classification number: G01N33/561 ,  C12M33/00 ,  G01N27/44739 ,  G01N27/44747 ,  G01N27/44778 ,  G01N33/54386 ,  G01N33/6842 ,  G01N33/92 ,  G01N2333/775 ,  G01N2550/00 ,  G01N2800/32 ,  G01N2800/50 ,  G01N2800/52

Abstract: Disclosed are methods and apparatus for separation of biomolecules via two-dimensional gel electrophoresis, methods and apparatus for immunoblotting separated biomolecules, and methods for the use of biomolecules processed via the methods and apparatus of the present invention, including use in a clinical setting. The methods and apparatus for separation of biomolecules via two-dimensional gel comprises vertical agarose gel electrophoresis in the first dimension, and the electrophoresis of a novel non-denaturing 3-35% concave gradient polyacrylamide gel in the second dimension. This novel gel can be cast in a modified gel caster that can facilitate the pouring of multiple gels simultaneously. The methods and apparatus for immunblotting are useful with any type of immunoblotting, including Western blot, Northern blot, and Southern blot analyses. These methods and apparatus provide safe, efficient and cost-effective immunoblots, while facilitating the reduction of exposure to toxic or radioactive materials, as well as the disposal of those materials.

Abstract translation: 公开了通过二维凝胶电泳分离生物分子的方法和装置，用于免疫印迹分离的生物分子的方法和装置，以及使用通过本发明的方法和装置处理的生物分子的方法，包括在临床环境中的用途。 通过二维凝胶分离生物分子的方法和装置包括第一维中的垂直琼脂糖凝胶电泳和第二维中新型非变性3-35％凹梯度聚丙烯酰胺凝胶的电泳。 这种新型凝胶可以浇铸在改良的凝胶浇铸机中，可以同时使多个凝胶倾倒。 用于免疫印迹的方法和装置可用于任何类型的免疫印迹，包括Western印迹，Northern印迹和Southern印迹分析。 这些方法和设备提供安全，有效和经济有效的免疫印迹，同时有助于减少暴露于有毒或放射性物质以及处理这些材料。

公开(公告)号：US20110244500A1

公开(公告)日：2011-10-06

申请号：US13065886

申请日：2011-04-01

Applicant: Howard K. Shapiro

Inventor： Howard K. Shapiro

IPC: C12Q1/37 ,  C07K14/00

CPC classification number: G01N33/6803 ,  C07K14/47 ,  G01N33/6848 ,  G01N2550/00

Abstract: The instant disclosure describes an electrophoretic procedure capable of resolving and isolating ultra high molecular weight (MW) protein aggregates from nerve tissue. The procedure is based on the use of composite agarose-polyacrylamide gel electrophoresis (CAPAGE) and resolves proteins and protein aggregates over the range of from approximately 225 kDa to approximately 30,000 kDa. Triton X-100 precipitation is used to obtain a cytoskeleton protein fraction that is subsequently resuspended and subjected to gel electrophoresis. This method demonstrates that a protein aggregate of approximately 30,000 kDa is characteristic of normal murine spinal cord tissue and that the amount of said protein aggregate is increased in spinal cord homogenate obtained from transgenic mice bearing copies of a mutant human gene characteristic of familial amyotrophic lateral sclerosis. This method for separating nerve tissue ultra high MW cytoskeleton protein aggregates can prove useful in a variety of future biophysical and pharmacological studies related to the etiologies of Charcot-Marie-Tooth disease, Alzheimer's disease, Parkinson's disease, diseases based on expansions in tandem DNA repeats, spinal muscular atrophy, Friedreich's ataxia, giant axon neuropathy, juvenile ceroid-lipofuscinosis, amyotrophic lateral sclerosis, diabetic polyneuropathy and Down's syndrome.

Abstract translation: 本公开描述了能够从神经组织中分辨和分离超高分子量（MW）蛋白聚集体的电泳方法。 该程序基于使用复合琼脂糖 - 聚丙烯酰胺凝胶电泳（CAPAGE），并且解析了在约225kDa至约30,000kDa范围内的蛋白质和蛋白质聚集体。 Triton X-100沉淀用于获得随后重悬浮并进行凝胶电泳的细胞骨架蛋白质级分。 该方法证明，约30,000kDa的蛋白质聚集体是正常鼠脊髓组织的特征，并且所述蛋白质聚集体的量在从具有家族性肌萎缩性侧索硬化特征的突变型人基因拷贝的转基因小鼠获得的脊髓匀浆中增加 。 用于分离神经组织超高MW细胞骨架蛋白聚集体的这种方法可以证明在与Charcot-Marie-Tooth疾病，阿尔茨海默氏病，帕金森病，基于串联DNA重复扩增的疾病相关的各种未来生物物理学和药理学研究中有用 脊髓性肌肉萎缩，弗里德里希共济失调，巨型轴突神经病变，青少年蜡状脂肪炎，肌萎缩性侧索硬化，糖尿病多发性神经病和唐氏综合征。